To The Moon

Hey Tigers!🐯 A 15.68% jump in Carvana and double-digit gains in cruise lines and defence stocks make a lively earnings leaderboard. But the biggest one-day winner is not automatically the strongest next-quarter opportunity. My take: L3Harris, Lilly and NXP deserve the closest fundamental follow-up. Carvana offers stronger growth momentum with greater price risk. Norwegian, Chipotle and MGM still need to prove that operating improvement can turn into durable earnings. 1 | When Did the Earnings Actually Arrive? Data as Oct29th 2026, Source Tiger Brokers. For TSCO and TPR, a specific independent catalyst for the October 29 advance was not established. For IR, the fresh release belongs to the after-close information set. My filter: first identify the catalyst; then separate repeatable operatin

Strong earnings are supporting the market — but cash flow, guidance and interest rates are deciding which stocks investors reward. Hey Tigers! 🐯 Q3 earnings season is gathering pace, but this week has made one thing clear: a strong headline result does not guarantee a higher share price. Microsoft and Alphabet reported after the October 28 close, delivering very different signals about the AI investment cycle. Microsoft’s cash generation strengthened its growth story. Alphabet’s revenue miss and deeper cash burn kept investors focused on the cost of expansion. Meanwhile, the Federal Reserve held interest rates unchanged, leaving companies and investors facing continued uncertainty over borrowing costs. My view: earnings can support the market’s recovery, but the next leg higher will requir

The Federal Reserve's next interest-rate decision is approaching, and investors are watching closely for clues about where monetary policy goes from here. While markets largely expect the Fed to keep rates unchanged, the bigger question is whether policymakers will signal that further tightening remains on the table. For ETF investors, the outcome could have different implications for growth stocks, long-term Treasury bonds and small-cap companies. Here are three ETFs to watch as the Fed prepares to announce its decision. Why the Fed's Decision Matters At its September meeting, the Federal Open Market Committee (FOMC) raised the federal funds target range by 25 basis points to 3.75%–4.00%, citing elevated inflation. The Fed's October meeting concludes on October 28, with the decision sched

Hi, tigers🐯 On October 26, Anthropic — the AI startup behind the Claude model family — publicly filed its S-1 registration statement with the SEC, setting the stage for what could be the largest IPO of the year. The company plans to list on the Nasdaq under the ticker $Anthropic(ANT)$, with a target debut window in November ahead of the U.S. midterm elections. The filing lifts the curtain on a web of deep ties between Anthropic and the world's largest tech and cloud companies — companies that are simultaneously investors, customers, suppliers, and distribution channels. For investors who can't get direct allocation in the IPO, these public market names may offer the closest proxies. 📌 Key Takeaways

🐯 Profits Up, Stocks Down? TSLA, NFLX and JPM Face Their Next Test As of October 27, 2026 | Recent releases from October 13–21 | All outlooks below are editorial scenarios Hey Tigers! 🐯 Earnings season is giving investors plenty of numbers to digest. But the question for your portfolio is what those numbers mean for the next quarter — and how much optimism the stock already prices in. Tesla’s cash flow recovered sequentially while profit remained under pressure. Netflix delivered stronger margins but a slower growth outlook. JPMorgan showed broad business strength alongside credit costs and a more cautious approach to share repurchases. [1–3] My take: earnings quality and the next earnings revision deserve more weight than the headline growth rate. Here are three widely followed names wort

Which U.S. stocks are Wall Street analysts becoming more bullish or bearish on? Last week’s analyst rating changes highlighted diverging views across AI software, semiconductors, technology hardware, financial services, and consumer-facing businesses. Investors should distinguish between three types of changes: Rating Upgrade: An analyst raises a stock's rating, such as from Hold to Buy. Rating Downgrade: An analyst lowers a rating, such as from Buy to Hold. Price Target Revision: An analyst changes the expected price level without necessarily changing the stock rating. Below are selected examples of reported analyst actions during the week. 1. Stocks Receiving Analyst Upgrades Ticker Brokerage Rating Change Latest Price Target $Datadog(DDOG)$ Ber

The AI trade hit a fresh test on October 22. The Nasdaq Composite plunged 2.6% to 26,008.86, its steepest daily percentage decline since June, as investors reconsidered the cost of the AI boom. The S&P 500 fell 1.21%, while the Philadelphia Semiconductor Index sank 6.7%. The pressure was especially visible in companies tied to the AI investment race. $Meta Platforms, Inc.(META)$ dropped around 7% even after reporting quarterly revenue above expectations, as investors focused on its mounting AI-related spending and plans to raise capital. The bigger question is whether heavy AI investment will generate returns quickly enough to justify the bill. For traders expecting further weakness, inverse ETFs offer a way to take bearish exp

Semiconductor stocks are recovering from a sharp selloff, while $NVIDIA(NVDA)$ 's upcoming keynote and Micron's record earnings put the AI supply chain back in focus. Hey Tigers! 🐯 After eight consecutive sessions of losses, semiconductor stocks finally rebounded on October 19. The Philadelphia Semiconductor Index (SOX) gained 1.6%, snapping a losing streak that had wiped approximately 15.7% off the index. The recovery comes just as Nvidia's GTC Berlin 2026 gets underway, with CEO Jensen Huang's keynote scheduled for October 21. Meanwhile, Micron's record earnings and strong demand for AI memory chips are providing further evidence of growth across the semiconductor supply chain. Can upcoming AI announcements and earnings turn this rebound into a

Morgan Stanley has initiated coverage on eight biotechnology companies spanning rare diseases, eye disorders, lung diseases and mental health. The firm sees significant potential in $PTC Therapeutics(PTCT)$ and $Belite Bio, Inc.(BLTE)$ , while $Trevi Therapeutics, Inc.(TRVI)$ and $COMPASS Pathways plc(CMPS)$ offer additional opportunities tied to clinical progress and potential commercialization. The common thread? Each company is developing treatments for conditions where existing options remain limited — creating potentially attractive markets, but also si

Hey Tigers! 🐯 Another week, another round of Wall Street analysts reassessing their favorite stocks. From AI software and semiconductor infrastructure to consumer brands and media companies, analysts sent mixed signals about where they see the biggest opportunities — and risks. Some companies received significant upgrades and higher price targets, while others faced growing concerns about valuations and future growth. Let's break down some of the week's most notable analyst calls from October 12–16, 2026! 👇 📅 Monday, Oct. 12: Salesforce Gets a Major AI-Era Upgrade 🤖 Stock Firm Rating Change Price Target 🟢 $Salesforce.com(CRM)$ $Bank of America(BAC)$ Underperform → Buy $285 🔴